D&D Pharmatech (XKRX:347850) Cash-to-Debt : 1.92 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. D&D Pharmatech's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.92.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, D&D Pharmatech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for D&D Pharmatech's Cash-to-Debt or its related term are showing as below:

XKRX:347850' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.94 Med: 6.25 Max: 44.78
Current: 1.92

During the past 6 years, D&D Pharmatech's highest Cash to Debt Ratio was 44.78. The lowest was 0.94. And the median was 6.25.

XKRX:347850's Cash-to-Debt is ranked worse than
67.63% of 1523 companies
in the Biotechnology industry
Industry Median: 6.39 vs XKRX:347850: 1.92

D&D Pharmatech Cash-to-Debt Historical Data

The historical data trend for D&D Pharmatech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

D&D Pharmatech Cash-to-Debt Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

44.78

10.58

1.74

0.94

1.92

D&D Pharmatech Quarterly Data
	Dec22	Sep23	Dec23
Cash-to-Debt	0.94	2.14	1.92

Competitive Comparison of D&D Pharmatech's Cash-to-Debt

For the Biotechnology subindustry, D&D Pharmatech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

D&D Pharmatech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's Cash-to-Debt falls into.

D&D Pharmatech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

D&D Pharmatech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15642.053	/	(3013.681	+	5120.622)
	=	1.92

D&D Pharmatech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15642.053	/	(3013.681	+	5120.622)
	=	1.92

D&D Pharmatech (XKRX:347850) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

D&D Pharmatech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech (XKRX:347850) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech (XKRX:347850) Headlines

No Headlines